Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
2. The election without traverse filed 09/09/2026 in response to the Office Action of 07/15/2026 is acknowledged and has been entered.
Applicant has elected Group I, claims 30-38, drawn to a polypeptide chain comprising: (a) a first ligand binding fragment of human NKG2D; (b) a second ligand binding fragment of human NKG2D; and (c) an Fc domain of a human immunoglobulin comprising: (i) a CH2 domain; and (ii) a CH3 domain.
3. Claims 30-49 are pending in the application. Claims 39-49 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 09/09/2026.
4. Claims 30-38 are currently under prosecution.
Priority
5. Applicant’s claim under 35 U.S.C. §§ 119(e), 121 and 365(c) for benefit of the earlier filing date of applications, is acknowledged.
6. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Claim Rejections - 35 USC § 102
7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
8. Claims 30-38 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Dranoff et al. (US 20110311535, December 22, 2011, IDS).
Claims 30-38 are herein drawn to a polypeptide chain comprising: (a) a first ligand binding fragment of human NKG2D; (b) a second ligand binding fragment of human NKG2D; and (c) an Fc domain of a human immunoglobulin comprising: (i) a CH2 domain; and (ii) a CH3 domain.
Dranoff et al. teach a composition comprising a NKG2D-Fc chimera and a pharmaceutically acceptable carrier, wherein the NKG2D-Fc chimera binds to one or more NKG2D ligands; see entire document, e.g. claims 1-11, abstract, [0007-0012], Fig. 1. Dranoff et al. teach that a recombinant NKG2D-Fc molecule can form a dimer by virtue of the hinge region of the Fc fragment that mediates dimer formation by disulfide bonding (see [0035], [0078]), which would be the same as the instant invention of Fig. 1.
For claim 31, Dranoff et al. teach that the NKG2D-Fc chimera comprises an NKG2D extracellular domain; see [0010], claim 5.
For claim 34, Dranoff et al. teach the ligand-binding domain of human NKG2D coupled to the Fc region of human IgG1; see [0030].
For claims 35-37, Dranoff et al. teach that the NKG2D-Fc chimera comprises a linking molecule, wherein the linker is a flexible peptide linker, wherein the linker comprises two or more of the following amino acids: glycine, serine, alanine, and threonine; see claims 2-4, [0066-0067].
Double Patenting
9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.
10. Claims 30-38 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-14 of U.S. Patent No. 10,865,232. Although the conflicting claims are not identical, they are not patentably distinct from each other because for the following reasons:
Claims 30-38 are herein drawn to a polypeptide chain comprising: (a) a first ligand binding fragment of human NKG2D; (b) a second ligand binding fragment of human NKG2D; and (c) an Fc domain of a human immunoglobulin comprising: (i) a CH2 domain; and (ii) a CH3 domain.
Claims 1-14 of U.S. Patent No. 10,865,232 are drawn to a dimeric NKG2D-Fc chimera including two distinct NKG2D ligand binding sites, each NKG2D ligand binding site attached to an Fc fragment, wherein: each NKG2D ligand binding site comprises NKG2D or a ligand binding portion of NKG2D; and the Fc fragment comprises a fragment crystallizable region (Fc) of an immunoglobulin.
Conclusion
11. No claim is allowed.
12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YAN XIAO whose telephone number is (571)270-3578. The examiner can normally be reached M-F 8-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached on 571-270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/YAN XIAO/Primary Examiner, Art Unit 1642